Oncocyte Corporation Begins Manufacturing of Transplant Blood Test
Precision diagnostics company, Oncocyte Corporation (Nasdaq: OCX), is addressing a market of more than one million annual testing opportunities in the United States as it begins manufacturing its transplant blood test.
Oncocyte believes its patented method of assessing graft damage offers distinct benefits over competing and more invasive approaches. Early access for the company’s Research Use Only (RUO) kit is expected to open in late Q4 2023.
Oncocyte has begun the manufacturing process for the distributable version of its patented transplant technology.
The assay provides a method of checking for signs of graft damage in transplant recipients, measuring levels of donor derived cell-free DNA in the blood.
The test provides a simple, easy-to-use workflow, on droplet digital PCR, so researchers can perform in-house testing. It can typically be accomplished within the same day, without the necessity of donor genotyping.
Oncocyte is a precision diagnostics company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and pipeline test DetermaCNI™ is a blood-based monitoring tool for assessing therapeutic efficacy in cancer patients. VitaGraft™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation. For more information, visit www.oncocyte.com or LinkedIn for updates.